PubMedClinical and translational science2026-11-17
Nine-Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data.
Le Goff Romane R, Gouverneur Amandine A, Collin Cédric C, Rabiega Pascaline P et al.
Type 2 diabetes (T2D) is a chronic condition with multimorbidity. Treatment strategies have evolved gradually over the past decades. We described longitudinal treatments, comorbidities, and healthcare resource utilization (HCRU) among adults with T2D in France between 2015 and 2023. The OREOT cohort included adults with T2D identified between 2015 and 2018 in IQVIA Electronic Medical Records and linked to the French National Health Data System. Patients were followed until 31 December 2023. Baseline characteristics, longitudinal clinical data, treatment patterns, incident comorbidities, and HCRU were assessed. Treatment trajectories were reconstructed using state sequence analysis. Among 236,305 patients, 57% were men, and the median age was 67 years. At baseline, 77% of patients had hypertension, 62% had dyslipidemia, and 57% had cardiovascular disease. Over a median follow-up of 8.7 years, body mass index and HbA1c remained stable, whereas renal markers worsened (mean eGFR -7 mL/min/1.73 m2). Incident comorbidities were frequent, particularly cancer (21%) and chronic kidney disease (11%). Metformin use declined (from 73% to 65%), while use of glucagon-like peptide-1 receptor agonists (from 5% to 18%), sodium-glucose cotransporter-2 inhibitors (from 0% to 17%), and insulin (from 16% to 22%) increased, alongside growing regimen complexity. Healthcare utilization was characterized by frequent primary care visits (median 49 GP visits), with limited endocrinology (21%) and nephrology (5%) involvement, and regular HbA1c monitoring, with a median of three tests per year. Overall, 20% of patients died during follow-up. Between 2015 and 2023, T2D management in France shifted toward newer and more complex therapies, while a high burden of comorbidities and progressive renal decline persisted, highlighting the need for coordinated care and long-term real-world evaluation of newer glucose-lowering therapies.